Drugs / PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E))
PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E))
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07675629 | Sep 2026 → Aug 2028 expected | — | Worcester HIV Vaccine | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07675629 ↗ |
| Modality | Vaccine | “The Recombinant Protein Vaccines (gp120 (A, B, C, A/E)) contains equal amounts of 4 gp120 proteins.” NCT07675629 ↗ |
| Route | Intramuscular | “400 mcg Recombinant Protein Vaccines admixed with 800 mcg Alhydrogel, to be administered as a 1 mL (IM) injection” NCT07675629 ↗ |